Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Effect of Ketamine and Electroconvulsive Therapy on Suicidal Ideation
IRCT20241129063888N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoint: Change in suicidal ideation. Started Sep 2025; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20241129063888N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241129063888N1.